Mukherjea M, Mukherjee P, Biswas R
Int J Fertil. 1980;25(2):122-6.
Depo-Provera has been used as a long-acting injectable contraceptive. The results of the study carried out for more than 2 years indicate that the depot formulation of medroxyprogesterone acetate (DMPA, Depo-Provera) at a dose of 150 mg at 90-day intervals appears to be acceptable to some women of this part of India, though many of them experience menstrual problems. However, irregular and/or excessive menstrual bleeding diminishes with long-term use of the contraceptive and a high percentage of users become amenorrheic. No major adverse reactions were observed and the minor side effects are comparable to those reported for the oral contraceptives. There was a tendency for weight-gain by the patients and the endometrium became atrophic or "resting" with the prolongation of the therapy.
醋酸甲羟孕酮避孕针(Depo - Provera)一直被用作长效注射避孕药。一项持续两年多的研究结果表明,每90天注射一次150毫克剂量的醋酸甲羟孕酮长效制剂(DMPA,Depo - Provera),对印度这一地区的一些女性来说似乎是可以接受的,尽管她们中的许多人会出现月经问题。然而,长期使用这种避孕药后,月经不规律和/或过多出血的情况会减少,且很大比例的使用者会闭经。未观察到重大不良反应,轻微副作用与口服避孕药报告的副作用相当。患者有体重增加的趋势,随着治疗时间延长,子宫内膜会萎缩或“静止”。